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ABSTRACT 1 
Background: Mobile health technology can improve medication safety for older adults, for 2 
instance, by educating patients about the risks associated with anticholinergic medication use.  3 
Objective: This study’s objective was to test the usability and feasibility of Brain Buddy, a 4 
consumer-facing mobile health technology designed to inform and empower older adults to 5 
consider the risks and benefits of anticholinergics. 6 
Methods: Twenty-three primary care patients aged ≥60 and using anticholinergic medications 7 
participated in summative, task-based usability testing of Brain Buddy. Self-report usability was 8 
assessed by the System Usability Scale and performance-based usability data were collected for 9 
each task through observation. A subset of 17 participants contributed data on feasibility, 10 
assessed by self-reported attitudes (feeling informed) and behaviors (speaking to a physician), 11 
with confirmation following a physician encounter. 12 
Results: Overall usability was acceptable or better, with 100% of participants completing each 13 
Brain Buddy task and a mean System Usability Scale score of 78.8, corresponding to “Good” to 14 
“Excellent” usability. Observed usability issues included higher rates of errors, hesitations, and 15 
need for assistance on three tasks, particularly those requiring data entry. Among participants 16 
contributing to feasibility data, 100% felt better informed after using Brain Buddy and 94% 17 
planned to speak to their physician about their anticholinergic related risk. On follow-up, 82% 18 
reported having spoken to their physician, a rate independently confirmed by physicians. 19 
Conclusion: Consumer-facing technology can be a low-cost, scalable intervention to improve 20 
older adults’ medication safety, by informing and empowering patients. User-centered design 21 
and evaluation with demographically heterogeneous clinical samples uncovers correctable 22 
usability issues and confirms the value of interventions targeting consumers as agents in shared 23 
decision making and behavior change. 24 
 25 
Keywords: Medications; information technology; shared decision making; patient safety; user-26 
centered design; anticholinergics; human factors engineering; behavioral informatics; mobile 27 
health (mHealth); digital health (eHealth) 28 
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INTRODUCTION 29 
In the “new era of patient engagement,”1 interventions to improve the quality and safety 30 
of healthcare target not only the clinician, but also the patient, their family, and their social 31 
networks.2 Contemporary decision aids and shared decision-making tools for patients leverage 32 
mobile and web technologies, including app-based or online risk calculators and patient 33 
portals.3,4 These technologies are part of the broader landscape of consumer health information 34 
technology and mobile health (mHealth), in which a multitude of digital health applications have 35 
been developed to directly assist patients and their advocates in achieving health goals and 36 
promoting behavior change.5 The work reported here extends consumer-facing mHealth to 37 
address medication safety among older adults prescribed high-risk medications. Specifically, we 38 
tested the usability and feasibility of Brain Buddy, a consumer-facing mHealth application 39 
designed to improve awareness and identification of potentially harmful anticholinergic 40 
medications and ultimately reduce their use among older adults. 41 
Consumer-facing medication tools 42 
Recently, digital medication related decision aids have seen increased use, particularly 43 
mobile applications supporting medication adherence.6 Among older adults with chronic 44 
comorbid diseases, consumer-facing medication technologies may increase medication 45 
adherence and improve self-management,7,8 but researchers have called for increased research to 46 
demonstrate the usability, feasibility, and effectiveness of these technologies across patient 47 
populations.6,9,10 Additionally, research is needed to design and evaluate mHealth systems that 48 
improve not only medication adherence for chronically ill individuals, but also facilitate 49 
medication safety for broad populations, such as older adults. 50 
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Risk of harm from anticholinergic medication use by older adults 51 
Prolonged use of anticholinergic medications by older adults is associated with long-term 52 
cognitive impairment, strongly evidenced by dose-response relationships between 53 
anticholinergic exposure and incident mild cognitive impairment and dementia11-13 as well as 54 
brain atrophy in chronic anticholinergic users.14 Consequently, multiple organizations including 55 
the National Academy of Medicine and the American Geriatrics Society recommend against 56 
older adults’ use of anticholinergics.15-17 Nevertheless, studies report that 20-50% of older adults 57 
use prescription anticholinergics and estimates sometimes exceed 80%.18-20 A 2017 study 58 
reported anticholinergic use by 65% of Medicare beneficiaries.21 Older adults also use over-the-59 
counter (OTC) anticholinergics to relieve symptoms including insomnia, diarrhea, and pruritus, 60 
among others.22-25 61 
Testing Brain Buddy, consumer-facing mHealth technology for medication safety 62 
To reduce older adults’ use of anticholinergic medications, we designed Brain Buddy, a 63 
consumer-facing mHealth application to inform and activate older adults to initiate dialogue with 64 
a clinician regarding the risks and benefits of their anticholinergic medications. The application 65 
directly targeted anticholinergic users, rather than prescribers or pharmacists, for two reasons. 66 
First, to our knowledge, all prior interventions to reduce anticholinergic use targeted only clinical 67 
professionals, with varying success.26-30 Second, recent work demonstrates the potential of 68 
consumer-facing interventions for medication safety. Notably, direct-to-consumer educational 69 
materials in the EMPOWER and D-PRESCRIBE randomized trials eliminated or reduced 70 
benzodiazepine use in up to 43% of older adults.31,32 71 
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Brain Buddy was designed to address the user needs and requirements we documented in 72 
a prior investigation of anticholinergic users. That investigation found that older adults were 73 
unaware of the risks of using anticholinergics; would consider changing to an alternative 74 
treatment; and often viewed their physician as the primary source of medication information and 75 
decision making.33 These findings suggested the potential for an intervention targeting awareness 76 
and behavioral activation among patients (consumers). 77 
This study’s objective was to test Brain Buddy for usability and feasibility with older 78 
adult anticholinergic users. We expected that the iterative, user-centered design of Brain Buddy 79 
would result in acceptable self-reported and performance-based usability. We also expected 80 
participants using Brain Buddy would initiate conversations with their primary care provider 81 
regarding anticholinergic risks. 82 
METHODS 83 
The study involved cross-sectional usability and feasibility testing of Brain Buddy with 84 
older adults. Twenty-three participants performed usability tests and a subset of 17 participants 85 
with medium or high anticholinergic risk contributed feasibility data (Figure 1). The study was 86 
approved by the Indiana University Institutional Review Board and occurred February-May, 87 
2018. Testing was preceded by a roughly one-year period of iterative design and formative 88 
usability testing.  89 
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Figure 1. Study design. 90 
 91 
User-centered design and formative testing 92 
Brain Buddy was designed at the Brain Health Patient Safety Laboratory by a 93 
professional design team led by faculty with expertise in user-centered technology design and 94 
medication safety. The design team used an iterative, user-centered design approach, meaning 95 
empirically derived user needs and requirements were translated into prototypes, which were 96 
tested with intended end-users and redesigned over multiple rounds.34 97 
The design team met weekly for approximately one year. Design work evolved from 98 
concepts and sketches, to flow diagrams with screenshot mockups, to a high-fidelity interactive 99 
prototype running on a mobile device. Design decisions were informed both by prior research on 100 
anticholinergic use and usability principles for older adults.35-37 For example, Brain Buddy used 101 
linear navigation, large fonts, and minimal scrolling. The team consulted the risk visualization 102 
literature38-40 to identify multiple ways to communicate anticholinergic risk, then comparison-103 
tested the alternatives. 104 
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A staff user experience designer performed three rounds of formative usability testing 105 
with a total of 11 older adults (3-4 users per round). Participants were shown paper 106 
visualizations, screenshots, and educational content in all rounds. In Rounds 2 and 3 (n=8) they 107 
also interacted with a 5.5-inch Android Pixel XL phone running a prototype on the Marvel app 108 
simulator (marvelapp.com). Participants were probed to explain their understanding of the 109 
visualizations, offer feedback, and use the prototype for a set of scripted tasks while thinking 110 
aloud, with occasional follow-up probes. A similar procedure is described elsewhere.34,41 111 
Findings from each round of formative testing were used to further refine Brain Buddy; for 112 
example, the ultimate design used an analog temperature gauge to display risk, as this was the 113 
best understood visualization. The final design is described next. 114 
The Brain Buddy application 115 
For usability and feasibility testing, participants used a professionally developed version 116 
of Brain Buddy, implemented as a native Android mobile app. Screenshots in Figures 2 and 3 117 
illustrate Brain Buddy functionality, which included: onboarding tutorial; home screen (Figure 118 
2a); educational content about anticholinergic medications and risks associated with their use 119 
(Figure 3a); search, browse, and selection of medications from a list of definite anticholinergics 120 
(Figure 2b); data entry to calculate a personal risk score (Figure 2c); risk score visualization 121 
(Figure 2d); and a risk score report that can be saved and shared. Brain Buddy’s educational 122 
content included three animated videos (Figure 3b-d), created and produced for Brain Buddy by 123 
the design team in collaboration with a digital storyteller and professional illustrator. Each video 124 
tells the story of an older adult (with variation in sex, race, and Hispanic origin) who learns about 125 
anticholinergic medications, then consults with a physician or pharmacist about their personal 126 
risk and safer alternatives. Videos range in duration from 3.5-4.5 minutes and address multiple 127 
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symptoms treated by anticholinergic medications, potential risks of anticholinergic use, the 128 
availability of alternatives, and the importance of consulting with a clinician. 129 
Figure 2. Example screen captures from the Brain Buddy application. 130 
(a) Main menu
  
(b) Select medications
 
(c) Risk score data entry
 
  (d) Risk score display 
 
 
  131 
Figure 3. Screen captures of Brain Buddy education screen and custom-made educational 132 
videos. 133 
a) Videos (b-d) are 
accessible from 
Brain Buddy’s 
Education screen. 
 
Videos feature a) 
White, b) Latino, 
and c) Black main 
characters 
 
a) Fred (and Albert, his friend) 
 
b)  Roberto (and Diane, his daughter) 
 
c) Rose (and Emma, her pharmacist) 
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Participants and setting 136 
Participants were older adults with a scheduled primary care appointment with one of 137 
seven primary care providers at Eskenazi Health, a large urban community safety net health 138 
system in Indianapolis, Indiana, USA. Patients were included if they were aged 60 years or older 139 
and were prescribed at least one of the 13 commonly prescribed anticholinergics (Appendix A) 140 
in the prior three months. These medications account for most prescription anticholinergics in 141 
this patient population. Individuals were excluded if they resided outside the county or in a 142 
nursing home, did not have access to a telephone, reported a terminal illness, reported being 143 
treated for substance abuse, or scored 3 or lower on the six-item screener for cognitive 144 
impairment.42 Participants were enrolled during the scheduled study period, with the goal of 145 
enrolling approximately 20 individuals, a target we deemed high for usability testing43,44 and 146 
typical for feasibility testing of a behavioral intervention. 147 
Potential participants were identified by review of medical records in the regional health 148 
information exchange, using a query specifying age, next appointment, primary care provider, 149 
and medication dispensing records. Phone calls were then placed by the university’s research 150 
recruiting service to establish interest in the study and perform eligibility screening. A study 151 
research assistant contacted eligible individuals to arrange a meeting at the clinic on the day of 152 
their upcoming appointment. Participants were instructed to bring their medications with them. 153 
Procedure and data collection instruments 154 
Patients were consented in the clinic or exam room, then took part in a usability test and 155 
semi-structured pre-encounter interview lasting approximately 30-45 minutes combined, before 156 
being seen for their visit. 157 
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The usability test had the following steps: a) guided practice; b) observed actual use with 158 
personal data; and c) self-report usability evaluation. Guided practice consisted of a set of five 159 
tasks performed by the participant for the first time: Log in; Access education; Select 160 
medications; Obtain risk score; View risk report. The research assistant delivered verbal 161 
instructions to complete the task and what information to enter into the application. During 162 
actual use, participants were instructed to use Brain Buddy from beginning to end, entering their 163 
personal medication and demographic data to produce a personal anticholinergic risk score. 164 
When participants were deemed unable to progress on their own, they were prompted in 165 
progressive order with a question (“Is there something unclear on this screen?”), then verbal 166 
instructions (e.g., “You can tap on 'view report' to see your report”), then an offer to demonstrate 167 
(“Do you want me to show you and you repeat?”).  168 
The research assistant recorded performance-based usability observations on a structured 169 
observation instrument, noting for each task the user’s behaviors and utterances in the categories: 170 
completion; mistakes; efficiency; assistance needed; emotions; and other. Participants then rated 171 
usability of the entire application on a researcher-administered paper survey using a modified 172 
System Usability Scale (SUS).45 SUS is a well validated 10-item questionnaire with a five-point 173 
response scale from strongly disagree (1) to strongly agree (5). The modified version contains 174 
rewording of several items for ease of understanding by older adults.34,41 175 
During the ensuing pre-encounter interview, participants who received a medium or high 176 
anticholinergic risk score when using Brain Buddy were given an informational Conversation 177 
Starter brochure about anticholinergics and encouraged to talk to their physician about 178 
anticholinergic risk. They were then asked whether they felt better informed about medications 179 
that may be unsafe for them and whether they planned to talk to their physicians about 180 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MEDICATION SAFETY TECHNOLOGY     10 
 
potentially unsafe medications. Finally, they received an after-visit form for their physician to 181 
complete. The after-visit form was a 1-item questionnaire asking the physician whether, during 182 
the appointment, they had discussed with the patient medication safety related to the listed 183 
anticholinergic medications. Participants who received a low anticholinergic risk score for any 184 
reason, including software malfunction (a fault in the code) in two cases, did not receive a 185 
Conversation Starter and after-visit form and were not further interviewed. 186 
Following the visit, the research assistant collected after-visit forms from physicians and 187 
attempted to contact participants by phone in the ensuing 24 hours for a post-encounter 188 
interview. Post-encounter interviews asked participants whether (and how) they discussed 189 
medication safety with their physician on the day of the visit and whether (and how) they had 190 
discussed medication safety with anyone else. Research staff also collected demographic 191 
information by phone. At the end of the study, participants were mailed a $20 gift card. 192 
Analysis 193 
Descriptive statistics were calculated on observed performance-based usability indicators, 194 
SUS items and scale score, and attitudes and behaviors self-reported by patients and their 195 
physicians. We defined acceptable subjective usability as above-average SUS scale scores 196 
relative to national norms, i.e., a score > 68.46,47 For performance-based usability testing we used 197 
a cut-off of 70%. Quantitative data were exported from secure research software (REDCap), 198 
cleaned in Microsoft Excel, and analyzed in IBM SPSS V25. Qualitative researcher notes from 199 
usability sessions and interviews were examined for illustrative examples but not systematically 200 
analyzed.  201 
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RESULTS 202 
Of those individuals reporting demographics, mean age was 67.6 (SD = 7.8, range 60-203 
85), 61% were female, and 54% identified as Black or African American and 31% as White. 204 
Participants reported being insured by Medicare (69%), Medicaid (38%), or other public 205 
insurance (23%), with 38% insured by multiple plans. About one-fourth (23%) had not attained a 206 
high-school diploma and another 23% had Master’s or professional degrees; the rest had a high-207 
school diploma (15%) or some college or vocational training (46%). The majority (69%) had an 208 
annual household income less than $25,000 and 92% less than $35,000.  209 
Usability 210 
Performance-based usability indicators from the 23 usability test participants are reported 211 
for each of five tasks in Table 1. Every study participant was able to complete every task. Most 212 
individuals completed the tasks without mistakes, although 46% of participants made at least one 213 
mistake when selecting medications from a list. For example, a participant with hand tremors 214 
accidentally tapped a medication and had to remove it. Mistakes were also made by 25-30% of 215 
participants when accessing education and entering risk data. Examples of mistakes were: 216 
tapping icon or header to activate a link, not the link itself; accidental selection of a medication; 217 
attempting to proceed to the next screen before completing all risk-related data entry (this 218 
anticipated error launched a pop-up error message).  219 
At least one-quarter of individuals were observed to pause or hesitate during the 220 
education, medication selection, and data entry tasks, signs of inefficiency in product use. In 221 
most cases, tasks were completed without assistance or with verbal encouragement. 222 
  223 
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Table 1. Observed usability indicators by task (n=23). 224 
 Tasks 
Usability element, N (%) LOG-IN EDU-
CATIONa 
SELECT 
MEDS 
ENTER 
RISK DATA 
VIEW RISK 
SCORE 
Completion 
   Finished task 
   Could not do it / gave up 
 
23 (100) 
0 (0) 
 
8 (100) 
0 (0) 
 
23 (100) 
0 (0) 
 
23 (100) 
0 (0) 
 
23 (100) 
0 (0) 
Mistakes 
   No mistakes 
   Mistakes / had to redo or 
undo 
 
21 (91) 
2 (9) 
 
6 (75) 
2 (25) 
 
13 (54) 
11 (46) 
 
16 (70) 
7 (30) 
 
22 (96) 
1 (4) 
Efficient use 
   Quick / fluid work 
   Pauses / delays / hesitation 
 
22 (96) 
1 (4) 
 
6 (75) 
2 (25) 
 
14 (61) 
9 (39) 
 
15 (65) 
8 (35) 
 
21 (91) 
2 (9) 
Assistance neededb 
   None needed 
   Needed encouragement 
   Needed more instructions 
   Needed demonstration 
 
20 (87) 
3 (13) 
0 (0) 
0 (0) 
 
5 (62) 
2 (25) 
3 (37) 
0 (0) 
 
9 (39) 
6 (26) 
10 (43) 
3 (13) 
 
14 (61) 
5 (22) 
8 (35) 
1 (4) 
 
22 (96) 
1 (4) 
0 (0) 
0 (0) 
Emotional responsec 
   Satisfied / smiling / nodding 
   Upset / frustrated / mad 
 
22 (96) 
1 (4) 
 
6 (75) 
2 (25) 
 
18 (78) 
4 (17) 
 
20 (87) 
2 (9) 
 
19 (83) 
4 (17) 
Underlining indicates < 70%. LOG-IN = log in and get started; EDUCATION = read and view 225 
educational content; SELECT MEDS = select medications from a list; ENTER RISK DATA = 226 
enter age, gender, stroke history; VIEW RISK SCORE = view computed risk score and risk 227 
report.  aThe education task was not mandatory for those who viewed educational materials 228 
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during the guided practice session preceding the test. bAn individual may have received multiple 229 
kinds of assistance. cIf observed. 230 
The mean usability score on the SUS was 78.8 and the median was 82.5 (SD = 15.7, 231 
range 37.5-97.5). The distribution of SUS scores was skewed left (skewness = -0.91, standard 232 
error = 0.48) but marginally normal. SUS norming data suggest 80.3 as the cut-off for an “A” 233 
grade, corresponding to the top 10% of scores from over 500 evaluations.46,47 Brain Buddy’s 234 
SUS score falls into the “Good” (mean SUS = 71.4) to “Excellent” (mean SUS = 85.5) range 235 
with respect to adjective ratings reported in Bangor and colleagues’ analysis of 959 236 
evaluations.47 Table 2 reports participant responses on the ten SUS items. Items corresponding to 237 
ease of use had higher ratings, whereas intention to use and learnability ratings were slightly 238 
lower.48 239 
Feasibility 240 
Six of the participants in the usability test received a low anticholinergic risk score, either 241 
as a result of software malfunction, because they were no longer using anticholinergics, or in one 242 
case because the participant did not correctly input their medications. These individuals were not 243 
asked about their attitudes and behavior with respect to anticholinergic medication risk. The 244 
remaining 17 who received a medium or high risk score reported feeling better informed (100%) 245 
and planning to talk to their physician about anticholinergic medication risks (94%) (Figure 4). 246 
In a follow-up interview after their clinic visit, 82% of these 17 reported having indeed talked to 247 
their physician and 35% also spoke to a family member or nurse. For 11 of these 17 participants, 248 
a physician completed the post-visit form indicating whether they had talked to the patient about 249 
their anticholinergic medications, with nine of 11 (82%) indicating they had. Although not 250 
systematically assessed, several individuals volunteered their plans to replace an anticholinergic 251 
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medication with a safer alternative, illustrated by one participant’s comment, “It became a 252 
situation where he's going to take me off the medication and replace it with another med.” 253 
Table 2. Responses on positively- (#1-5) and negatively-worded (#6-10) SUS items (n=23). 254 
 Response, N (%)  
SUS item Strongly 
agree 
Agree Neither 
agree/ 
disagree 
Disagree Strongly 
disagree 
% 
usable 
1. Would use frequently 8 (35) 9 (39) 2 (9) 3 (13) 1 (4) 74% 
2. Easy to use 12 (52) 10 (43) 0 (0) 1 (4) 0 (0) 96% 
3. Parts well integrated 6 (26) 13 (57) 3 (13) 0 (0) 1 (4) 83% 
4. Learning was quick  10 (43) 10 (43) 0 (0) 2 (9) 1 (4) 87% 
5. Felt confident using 7 (30) 12 (52) 2 (9) 1 (4) 1 (4) 83% 
6. Would need help to use 1 (4) 4 (17) 1 (4) 6 (26) 11 (48) 74% 
7. Was confusing for me 0 (0) 1 (4) 1 (4) 8 (35) 13 (57) 91% 
8. Too complex for me 2 (9) 1 (4) 2 (9) 5  (22) 13 (57) 78% 
9. Was hard to use 0 (0) 0 (0) 1 (4) 8 (35) 14 (61) 96% 
10. Would need to learn a lot 
to use 
0 (0) 5 (22) 1 (4) 6 (26) 11 (48) 74% 
SUS = System usability scale. Negatively-worded items are printed in italics. % usable indicates 255 
percent of respondents indicating agreement on positively-worded and disagreement on 256 
negatively-worded items.  257 
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Figure 4. Attitudes and self-reported behaviors (left) and physician confirmation* (right). 258 
 259 
*A post-visit report could not be collected from the participant’s physician in six cases. 260 
DISCUSSION 261 
In this study we performed usability and feasibility testing of Brain Buddy, a consumer-262 
facing mHealth technology designed to reduce the risk of anticholinergic medications among 263 
older adults. mHealth technologies such as Brain Buddy can be powerful enablers of patients 264 
because they can provide just-in-time information access, efficient and effective communication 265 
channels, and continuous support.49 mHealth can also democratize knowledge and reduce 266 
information asymmetry between patients and healthcare professionals, integrate large amounts of 267 
data from multiple sources, and present information in ways that support better decision 268 
making.50 However, it is increasingly evident that mHealth technologies, especially for older 269 
adults, must be designed in a user-centered fashion and tested for usability, acceptability, and 270 
feasibility in real-world clinical settings.10,51 Moreover, national studies show enduring digital 271 
divides among older adults, particularly gaps disadvantaging racial and ethnic minorities.52,53 To 272 
avoid the phenomenon known as intervention-generated inequalities, produced by a focus on 273 
technologies and other interventions that help the ‘haves’ and hurt the ‘have nots,’54 it is 274 
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important to perform studies of usability, acceptability, and feasibility with demographically and 275 
socioeconomically diverse samples. 276 
Usability 277 
Brain Buddy was found to have acceptable usability for a demographically diverse 278 
sample of 23 older adults receiving primary care in a community health center. Self-reported 279 
usability scores were generally high, averaging between “Good” and “Excellent” and well above 280 
the normative average.47 Like other recent studies with older adults reporting SUS scores for 281 
mHealth applications or medical devices,34,41,55 we found some individuals reported low usability 282 
and made mistakes during use, especially on tasks requiring data entry. Very low scores, for 283 
example one outlying SUS score of 37.5 (> 2.5 SD of the mean), suggest even further redesign 284 
may not yield a product that everyone can use, due to disability, unease, or other factors.56 285 
Design changes can reduce certain errors, for example, by increasing the distance between 286 
buttons to minimize accidental button presses, whereas other mistakes are inevitable and the 287 
design goals should be to increase error recovery.57 Examples of error recovery in the Brain 288 
Buddy are the ability to quickly edit accidentally selected medications and prominent back-289 
navigation buttons. It is also possible that the design of Brain Buddy was reasonably usable, but 290 
that participants found medication-related tasks difficult due to pre-existing medication 291 
knowledge gaps; for example, a recent study reported 30% of their sample (mean age = 53) had 292 
difficulty naming at least one of their medications.58 Future design could supplement written 293 
medication names with photos, to capitalize on individuals’ knowledge of their medications’ 294 
color, shape, and size.59 Another strategy to circumvent medication knowledge gaps, as well as 295 
reduce burden and errors related to data entry, is using automation or passive sensing (the 296 
collection of data through sensors with no or minimal effort on the part of the individual).60 297 
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Although overall usability was acceptable, participants self-reported lower scores on 298 
learnability items (needing to learn, needing assistance), not surprising given participants were 299 
using Brain Buddy for the first time and some had never used a smartphone. We also observed 300 
that to perform more difficult tasks, up to 61% of participants needed encouragement, further 301 
instructions, and in a few cases demonstration by research staff. Learnability issues can be 302 
addressed with initial training, either in-person or via in-app tutorials, as well as clear 303 
instructions and help functionality.61 Another possibility is designing the app for use by a proxy 304 
or with assistance, for example a family member who can provide encouragement, verbal 305 
instructions, or demonstrate use. The concept of designing medication aids for proxy or joint use 306 
has been explored among caregivers of juvenile patients,62 but should be further studied with 307 
products for older adults. 308 
Feasibility 309 
All participants who provided feasibility data reported feeling better informed after using 310 
Brain Buddy and nearly all planned to speak to a physician about anticholinergic related risks. 311 
Additionally, 82% did indeed speak to their physician about anticholinergics and although we 312 
did not measure actual changes in medications, some reported self-initiating alternative therapies 313 
with their physician. This study was designed to initiate and measure patients’ conversations 314 
with a physician, based on prior work on older adults’ deference to physicians regarding both 315 
prescription and nonprescription medications.33,63 While our findings support Brain Buddy’s 316 
efficacy in initiating conversations, these findings should be treated with caution because of the 317 
small sample size, lack of control group, and no measure of actual changes in prescriptions and 318 
medication use. 319 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MEDICATION SAFETY TECHNOLOGY     18 
 
It remains to be seen whether informing and activating older adults effectively changes 320 
prescribing behavior, compared to prescriber-oriented interventions. However, first, we believe 321 
consumer-oriented interventions can complement rather than replace interventions targeting 322 
physicians, pharmacists, and other clinicians. In a recent Cochrane review of interventions to 323 
reduce inappropriate use of medications in older adults, 11 of 12 (92%) controlled studies 324 
targeted clinicians;64 this suggests unexplored opportunities to introduce consumer-oriented 325 
medication safety interventions.31 Further work should examine the best way to combine 326 
consumer- and clinician-facing interventions for medication safety. Second, if effective, 327 
interventions using direct-to-consumer mHealth offer an inexpensive and scalable solution. We 328 
note prior attempts to influence anticholinergic medication use through physician-oriented 329 
interventions such as computerized provider order entry alerts or involving geriatricians have 330 
been unsuccessful because physicians disregarded alerts or were effective but difficult to 331 
scale.26,65 Third, patients do indeed influence prescriber behavior. A series of studies published in 332 
the British Medical Journal demonstrated a considerable effect of patient requests and perceived 333 
patient preferences on prescribing activity.66-70 Fourth, activating patients to enter into shared 334 
decision making is an accepted, evidence-based strategy underpinning new paradigms of 335 
healthcare delivery.71,72 Therefore, rather than ask whether to target patients, a more relevant 336 
question is how to best achieve safer medication prescribing by leveraging patient involvement. 337 
Study strengths and limitations 338 
This study was performed on a technology designed and evaluated for usability at the 339 
outset, following standard user-centered design and testing methods.  We recruited older adults 340 
from a real-world primary care setting and targeted individuals known to be prescribed 341 
anticholinergic medications. We performed summative usability of the fully interactive, 342 
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professionally developed application in the field, with older adult users of anticholinergic 343 
medications. Our sample size of 23 was large compared to typical usability studies.43,44 We 344 
collected both self-report and observed performance-based usability data, important given the 345 
imperfect correlations between the two.73 In addition, for 17 participants, we collected data on 346 
their self-reported attitudes and behavior, independently confirmed by physician reports. Such 347 
data are critical for technologies relying on behavior change.74 The study was performed with 348 
patients differing in race, sex, and education, though predominantly non-White, less educated, 349 
and earning an annual household income < $25,000. Study limitations included testing with 350 
patients from a single health system who had no cognitive or visual impairment. We did not 351 
measure or recruit for diversity on literacy or health literacy, knowledge about medications, 352 
baseline patient activation, or other factors that may influence Brain Buddy usability and 353 
feasibility. In this study we did not measure comprehension of the educational videos, although 354 
these had been pre-tested with community stakeholders. Brain Buddy use occurred in the 355 
presence of a researcher and home use was not observed. As discussed above, we did not 356 
measure actual medication prescription, dispensing, or use behavior. The study did not have a 357 
control group, was cross-sectional, and had too small a sample size to draw conclusions about 358 
efficacy. Although our team included clinicians, we did not involve frontline clinicians in Brain 359 
Buddy design or testing. 360 
Conclusion 361 
In addition to addressing the above limitations, future work should examine how Brain 362 
Buddy and similar mHealth interventions can be used for other cases of medication safety or for 363 
nonpharmacological treatment. Additional work remains to integrate Brain Buddy and similar 364 
products into clinical workflow and technologies. Studies should test the costs, safety, and 365 
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efficacy (on prescribing, anticholinergic exposure, and cognition) of Brain Buddy alone and 366 
combined with other patient- and clinician-oriented medication safety interventions. Other work 367 
could examine paper-based versions of Brain Buddy or embed Brain Buddy in settings such as 368 
retail pharmacies. Furthermore, we recommend studies on strategies to ensure informing and 369 
activating patients result in safe medication changes over time and across contexts of care. This 370 
includes considerations for initiating and structuring patient-clinician communication about 371 
medication safety. For the time being, our findings support performing user-centered design and 372 
testing of mHealth and other digital health interventions, towards achieving older adult 373 
medication safety in a scalable and cost-effective manner.  374 
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Appendix A. Prescription anticholinergics used in eligibility screening. 
1. Cyclobenzaprine 
2. Oxybutynin 
3. Olanzapine 
4. Amitriptyline 
5. Hydroxyzine 
6. Paroxetine 
7. Quetiapine 
8. Meclizine 
9. Nortriptyline 
10. Dicyclomine 
11. Tolterodine 
12. Doxepin 
13. Methocarbamol 
 
